Physician profile
Anand Basi
NPI 1639270291
$5,716.13
in general payments reported to CMS, 2019-2025
39 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $431 · 2021: $973 · 2022: $787 · 2023: $741 · 2024: $880 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $935.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $829.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $456.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $454.24 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Mylan Specialty L.P. | $266.80 | 2019-2024 | Yupelri |
| Pfizer INC. | $264.65 | 2019-2025 | |
| Abbvie INC. | $259.83 | 2021-2024 | Ubrelvy, Vraylar |
| Sunovion Pharmaceuticals INC. | $232.13 | 2019-2022 | |
| Amgen INC. | $230.00 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.26 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.61 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $171.65 | 2023-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $123.81 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $107.37 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.33 | 2025 | Caplyta |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Basi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.